What is HC Wainwright’s Forecast for PVLA FY2026 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – HC Wainwright issued their FY2026 earnings per share estimates for Palvella Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($6.40) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($6.36) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q4 2026 earnings at ($1.94) EPS, Q1 2027 earnings at ($2.22) EPS, Q2 2027 earnings at ($2.83) EPS, Q3 2027 earnings at ($3.42) EPS, Q4 2027 earnings at ($3.10) EPS, FY2027 earnings at ($11.57) EPS, FY2028 earnings at ($9.87) EPS, FY2029 earnings at ($4.28) EPS and FY2030 earnings at $6.30 EPS.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, November 5th. The company reported ($1.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.08.

PVLA has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Oppenheimer upped their price objective on Palvella Therapeutics from $210.00 to $232.00 and gave the company an “outperform” rating in a research report on Friday. William Blair started coverage on Palvella Therapeutics in a research note on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Chardan Capital reissued a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a report on Wednesday, October 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $213.85.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $174.08 on Tuesday. The stock has a market capitalization of $2.51 billion, a PE ratio of -31.65 and a beta of -0.21. Palvella Therapeutics has a 52-week low of $72.22 and a 52-week high of $179.95. The company has a 50-day simple moving average of $143.02 and a two-hundred day simple moving average of $128.52.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PVLA. BlackRock Inc. bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth approximately $140,343,000. First Light Asset Management LLC grew its position in Palvella Therapeutics by 38.3% during the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after buying an additional 271,617 shares during the period. Jennison Associates LLC increased its holdings in Palvella Therapeutics by 65.3% during the first quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after buying an additional 253,128 shares during the last quarter. Primecap Management Co. CA purchased a new position in shares of Palvella Therapeutics during the 2nd quarter worth $39,150,000. Finally, Siren L.L.C. lifted its position in shares of Palvella Therapeutics by 243.3% during the 1st quarter. Siren L.L.C. now owns 257,485 shares of the company’s stock valued at $32,096,000 after buying an additional 182,485 shares in the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Palvella Therapeutics

In other news, Director George Jenkins sold 7,174 shares of the stock in a transaction on Tuesday, October 13th. The stock was sold at an average price of $130.36, for a total transaction of $935,202.64. Following the transaction, the director directly owned 139,790 shares of the company’s stock, valued at $18,223,024.40. This represents a 4.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Kiritsy sold 313 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total value of $49,141.00. Following the transaction, the director directly owned 250 shares in the company, valued at $39,250. The trade was a 55.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 61,056 shares of company stock worth $8,756,946. Insiders own 17.20% of the company’s stock.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $243 from $232 and maintained a Buy rating. The target implies substantial upside from the $174.08 reference price, although it is an analyst forecast, not a guarantee. Canaccord Genuity recommendations
• Positive Sentiment: HC Wainwright assigned Palvella a Strong-Buy rating and projects a longer-term earnings turnaround, forecasting positive EPS of $6.30 in 2030.
• Negative Sentiment: HC Wainwright expects continued losses in the intervening years, including a forecast loss of $11.57 per share for 2027, following estimated losses of $6.40 per share in 2026. These are analyst estimates, not company guidance.

Palvella Therapeutics Company Profile

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania.

Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Palvella is led by founder and Chief Executive Officer Wes Kaupinen.